当前位置: X-MOL 学术Hepatology › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Discovery of a Carbamoyl Phosphate Synthetase 1–Deficient HCC Subtype With Therapeutic Potential Through Integrative Genomic and Experimental Analysis
Hepatology ( IF 13.5 ) Pub Date : 2021-08-03 , DOI: 10.1002/hep.32088
Tong Wu 1 , Guijuan Luo 2 , Qiuyu Lian 3, 4 , Chengjun Sui 2 , Jing Tang 5 , Yanjing Zhu 1 , Bo Zheng 1 , Zhixuan Li 1 , Yani Zhang 6 , Yangqianwen Zhang 1 , Jinxia Bao 1 , Ji Hu 1 , Siyun Shen 1 , Zhao Yang 2 , Jianmin Wu 6 , Kaiting Wang 6 , Yan Zhao 6 , Shuai Yang 7, 8 , Shan Wang 7, 8 , Xinyao Qiu 7, 8 , Wenwen Wang 7, 8 , Xuan Wu 9 , Hongyang Wang 1, 2, 10 , Jin Gu 4 , Lei Chen 1, 7, 8, 10
Affiliation  

Metabolic reprogramming plays an important role in tumorigenesis. However, the metabolic types of different tumors are diverse and lack in-depth study. Here, through analysis of big databases and clinical samples, we identified a carbamoyl phosphate synthetase 1 (CPS1)-deficient hepatocellular carcinoma (HCC) subtype, explored tumorigenesis mechanism of this HCC subtype, and aimed to investigate metabolic reprogramming as a target for HCC prevention.

中文翻译:

通过综合基因组和实验分析发现具有治疗潜力的氨基甲酰磷酸合成酶 1 缺陷型 HCC 亚型

代谢重编程在肿瘤发生中起重要作用。但不同肿瘤的代谢类型多样,缺乏深入研究。在这里,通过对大型数据库和临床样本的分析,我们确定了一种氨基甲酰磷酸合成酶 1 (CPS1) 缺陷型肝细胞癌 (HCC) 亚型,探索了这种 HCC 亚型的肿瘤发生机制,旨在研究代谢重编程作为 HCC 预防的靶点.
更新日期:2021-08-03
down
wechat
bug